| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CD215 |
| WB Predicted band size | 28 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human IL15RA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL15RA抗体的3篇参考文献摘要示例(部分信息为模拟生成，仅供参考)：
---
1. **文献名称**: *Targeting IL-15 Receptor alpha with a Neutralizing Antibody Ameliorates Autoimmune Arthritis*
**作者**: Smith A, et al.
**摘要**: 研究开发了一种靶向IL-15Rα的中和抗体，通过阻断IL-15/IL-15Rα信号通路，显著减轻小鼠胶原诱导性关节炎模型的炎症反应和关节破坏，表明其在自身免疫疾病中的治疗潜力。
---
2. **文献名称**: *Structural Basis of IL-15 Receptor alpha Recognition by a Therapeutic Antibody*
**作者**: Lee B, et al.
**摘要**: 通过X射线晶体学解析了人源化抗IL-15Rα抗体与受体胞外域的复合物结构，揭示了抗体结合的表位及抑制IL-15信号转导的分子机制，为抗体药物优化提供了结构基础。
---
3. **文献名称**: *IL-15Rα-Specific Antibody Enhances Antitumor Immunity by Depleting Regulatory T Cells in Solid Tumors*
**作者**: Chen X, et al.
**摘要**: 研究报道了一种靶向IL-15Rα的抗体，通过选择性耗竭肿瘤微环境中的调节性T细胞(Tregs)，增强抗肿瘤T细胞活性，在黑色素瘤和结肠癌小鼠模型中显著抑制肿瘤生长。
---
如需具体文献，建议在PubMed或Sci-Hub中检索关键词“IL15RA antibody”或“anti-IL15RA therapy”获取最新研究。
Interleukin-15 receptor alpha (IL15RA) is a key component of the heterotrimeric IL-15 receptor complex, which also includes IL-2Rβ and the common gamma chain (γc). As a high-affinity binding subunit, IL15RA specifically interacts with IL-15. a pleiotropic cytokine critical for the development, survival, and activation of immune cells, particularly natural killer (NK) cells and memory CD8+ T cells. Structurally, IL15RA contains extracellular cytokine-binding domains, a transmembrane region, and a short cytoplasmic tail that facilitates signal transduction through JAK-STAT pathways.
Antibodies targeting IL15RA have emerged as valuable tools for modulating IL-15 signaling in both research and therapeutic contexts. In research, anti-IL15RA antibodies are used to block IL-15/IL15RA interactions, enabling studies on immune regulation, autoimmune diseases, and cancer immunology. Therapeutically, antagonistic anti-IL15RA antibodies are explored for treating autoimmune disorders like rheumatoid arthritis or inflammatory bowel disease by suppressing pathological immune activation. Conversely, agonist antibodies that mimic IL-15 trans-presentation (a unique mechanism where IL15RA presents IL-15 to neighboring cells) are being investigated to boost anti-tumor immunity. Challenges include balancing efficacy with potential off-target effects, as IL-15 signaling supports both pro-inflammatory and homeostatic immune functions. Recent preclinical studies highlight the potential of IL15RA-targeting bispecific antibodies and antibody-drug conjugates in precision immunotherapy. Overall, IL15RA antibodies represent a versatile strategy for immune modulation, with ongoing clinical trials evaluating their safety and therapeutic potential.
×
